Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$104.92 USD

104.92
1,086,526

-0.75 (-0.71%)

Updated Nov 12, 2024 04:00 PM ET

After-Market: $104.94 +0.02 (0.02%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks News

Novartis (NVS) Arm's Biosimilars Study Results Encourage

Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.

    Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised

    Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.

      Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y

      Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.

        Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus

        Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.

          What's in Store for Ligand (LGND) This Earnings Season?

          Ligand's (LGND) Captisol formulation technology that helps it form partnerships with several leading healthcare companies might drive the stock in Q3.

            Teva (TEVA) Stock Plunges 20% on Q3 Earnings Miss & View Cut

            Teva's (TEVA) third-quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.

              Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss

              Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.

                Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat

                Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.

                  Arpita Dutt headshot

                  5 Biotech and Pharma Stocks with Key FDA Catalysts this November

                  Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.

                    Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal

                    Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.

                      Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss

                      Aduro BioTech's (ADRO) third-quarter results were unimpressive with the company reporting loss as expected and revenues missing estimates.

                        Novartis Buys French Radiopharmaceutical Company

                        Novartis (NVS) plans to acquire France-based Advanced Accelerator Applications. The takeover will add RadioLigand Therapy, Lutathera, in its portfolio with potential to drive growth in the near term.

                          Advanced Accelerator (AAAP) in Focus: Stock Moves 10.4% Higher

                          Advanced Accelerator (AAAP) was a big mover last session, as the company saw its shares more than 10% on the day amid huge volumes.

                            What's in Store for Juno Therapeutics (JUNO) in Q3 Earnings?

                            Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q3.

                              Swarup Gupta headshot

                              Foreign Stock Roundup: Novartis, Bayer, Glaxo, Total Beat on Earnings

                              Political developments guided the movement of most non U.S. markets this week.

                                What's in Store for Conatus (CNAT) This Earnings Season?

                                Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q3. However, the company's current portfolio shows no approved product and revenue generation.

                                  The Zacks Analyst Blog Highlights: Visa, Coca-Cola, United Technologies, AT&T and Novartis

                                  The Zacks Analyst Blog Highlights: Visa, Coca-Cola, United Technologies, AT&T and Novartis

                                    Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss

                                    The Medicines Company (MDCO) incurs loss in the third quarter of 2017. The top line decreases year over year due to low Angiomax sales.

                                      Amgen (AMGN) Q3 Earnings Top, Sales Decline Y/Y, Stock Falls

                                      Though Amgen (AMGN) beat estimates on both earnings & sales and raised its earnings outlook, shares declined in after-hours trading due to the year-over-year decline in revenues.

                                        Drug Stock Q3 Earnings Roster for Oct 26: GILD, BMY & More

                                        Four major biotech giants are set to report third-quarter results on Oct 26. A sneak preview as to how things are shaping up for these companies.

                                          Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength

                                          Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.

                                            Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX

                                            The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.

                                              Arpita Dutt headshot

                                              Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider

                                              Will the FDA approval of Novartis and Gilead's (GILD) CAR-T cell therapies fuel more partnership deals and acquisitions in this space?

                                                Key Predictions for Q3 Earnings Reports of LLY, BIIB, NVS

                                                The pharma/biotech industry has seen a solid start to the Q3 earnings season as evident from J&J's solid results. Let's see if the other leading players -- Lilly, Biogen and Novartis -- follow suit.

                                                  Roche (RHHBY) Reports Sales Numbers for First 9 Months

                                                  Roche Holding AG's (RHHBY) reported sales of CHF39.4 billion in the first nine months of 2017, up 5% from the year-ago period.